Literature DB >> 6390917

Carcinoma in situ of the urinary tract.

D C Utz, G M Farrow.   

Abstract

The identification and description of carcinoma in situ by pathologists and the recognition of its clinical features and diagnostic clues by clinicians represent a significant advancement in the struggle to conquer invasive epithelial cancer in recent times. The authors discuss symptoms, diagnosis, pathologic features, and treatment.

Entities:  

Mesh：

Year:  1984        PMID： 6390917

Source DB:  PubMed          Journal:  Urol Clin North Am        ISSN： 0094-0143            Impact factor:   2.241


  6 in total

1.  Cellular morphological parameters of the human urinary bladder (malignant and normal).

Authors:  Ahmad Keshtkar; Asghar Keshtkar; Pat Lawford
Journal:  Int J Exp Pathol       Date:  2007-06       Impact factor: 1.925

Review 2.  Carcinoma in situ and treatment options.

Authors:  M Erton; Y Ilker
Journal:  Int Urol Nephrol       Date:  1996       Impact factor: 2.370

3.  Clinical outcome of primary versus secondary bladder carcinoma in situ.

Authors:  Daher C Chade; Shahrokh F Shariat; Ari Adamy; Bernard H Bochner; S Machele Donat; Harry W Herr; Guido Dalbagni
Journal:  J Urol       Date:  2010-06-17       Impact factor: 7.450

4.  Clinical outcomes of primary bladder carcinoma in situ in a contemporary series.

Authors:  Daher C Chade; Shahrokh F Shariat; Guilherme Godoy; Caroline J Savage; Angel M Cronin; Bernard H Bochner; S Machele Donat; Harry W Herr; Guido Dalbagni
Journal:  J Urol       Date:  2010-07       Impact factor: 7.450

5.  Importance of red patches diagnosed in cystoscopy for haematuria and lower urinary tract symptoms.

Authors:  Herman Fernando; Sreenivasa S Thota; Glyn Burtt; Nicholas Waterfall; Imtiaz Husain
Journal:  Postgrad Med J       Date:  2007-01       Impact factor: 2.401

6.  Immunopathologic analysis of human urinary bladder cancer. Characterization of two new antigens associated with low-grade superficial bladder tumors.

Authors:  C Cordon-Cardo; D D Wartinger; M R Melamed; W Fair; Y Fradet
Journal:  Am J Pathol       Date:  1992-02       Impact factor: 4.307
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.